Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers

Jensen, Jens Ulrik Stæhr; Itenov, Theis Skovsgaard; Thormar, Katrin M; Hein, Lars; Mohr, Thomas Tuff; Andersen, Mads H; Løken, Jesper; Tousi, Hamid; Lundgren, Bettina; Boesen, Hans Christian; Johansen, Maria Egede; Ostrowski, Sisse Rye; Johansson, Pär I; Grarup, Jesper; Vestbo, Jørgen; Lundgren, Jens; Procalcitonin And Survival Study (PASS) Group

Published in:
Annals of Intensive Care

DOI:
10.1186/s13613-016-0212-y

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Jensen, J. U. S., Itenov, T. S., Thormar, K. M., Hein, L., Mohr, T. T., Andersen, M. H., ... Procalcitonin And Survival Study (PASS) Group (2016). Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. DOI: 10.1186/s13613-016-0212-y

Download date: 19. Jul. 2018
Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial

Jens-Ulrik S. Jensen1,2*, Theis S. Itenov1,3, Katrin M. Thormar4,5, Lars Hein3,6, Thomas T. Mohr3,6, Mads H. Andersen7, Jesper Løken8, Hamid Tousi9, Bettina Lundgren2, Hans Christian Boesen6, Maria E. Johansen1, Sisse R. Ostrowski10, Pär I. Johansson10, Jesper Grarup1, Jørgen Vestbo11, Jens D. Lundgren1 and For The Procalcitonin And Survival Study (PASS) Group

Abstract

Background: It is unclear whether biomarkers of alveolar damage (surfactant protein D, SPD) or conductive airway damage (club cell secretory protein 16, CC16) measured early after intensive care admittance are associated with one-month clinical respiratory prognosis. If patients who do not recover respiratory function within one month can be identified early, future experimental lung interventions can be aimed toward this high-risk group. We aimed to determine, in a heterogenous critically ill population, whether baseline profound alveolar damage or conductive airway damage has clinical respiratory impact one month after intensive care admittance.

Methods: Biobank study of biomarkers of alveolar and conductive airway damage in intensive care patients was conducted. This was a sub-study of 758 intubated patients from a 1200-patient randomized trial. We split the cohort into a “learning cohort” and “validating cohort” based on geographical criteria: northern sites (learning) and southern sites (validating).

Results: Baseline SPD above the 85th percentile in the “learning cohort” predicted low chance of successful weaning from ventilator within 28 days (adjusted hazard ratio 0.6 [95% CI 0.4–0.9], \( p = 0.005 \)); this was confirmed in the validating cohort. CC16 did not predict the endpoint. The absolute risk of not being successfully weaned within the first month was 48/106 (45.3%) vs. 175/652 (26.8%), \( p < 0.0001 \) (high SPD vs. low SPD). The chance of being “alive and without ventilator \( \geq 20 \) days within the first month” was lower among patients with high SPD (adjusted OR 0.2 [95% CI 0.2–0.4], \( p < 0.0001 \)), confirmed in the validating cohort, and the risk of ARDS was higher among patients with high SPD (adjusted OR 3.4 [95% CI 1.0–11.4], \( p = 0.04 \))—also confirmed in the validating cohort.

Conclusion: Early profound alveolar damage in intubated patients can be identified by SPD blood measurement at intensive care admission, and high SPD level is a strong independent predictor that the patient suffers from ARDS and will not recover independent respiratory function within one month. This knowledge can be used to improve...
diagnostic and prognostic models and to identify the patients who most likely will benefit from experimental interventions aiming to preserve alveolar tissue and therefore respiratory function.

**Trial registration** This is a sub-study to the Procalcitonin And Survival Study (PASS), Clinicaltrials.gov ID: NCT00271752, first registered January 1, 2006

**Keywords:** Lung damage, Mechanical ventilation, Biomarkers, Personalized early intervention

**Background**

Persistent ventilator-dependent respiratory failure is a major cause of death and prolonged admission to the intensive care unit [1]. Some patients suffer damage to the respiratory system during the intensive care course and do not recover the ability to breathe independently. Among other biomarkers of lung damage (e.g., surfactant protein A [2], soluble receptor for advanced glycation end products (sRAGE) [3] and Kerbs von Lungen [3]), surfactant protein D (SPD), produced by alveolar type II cells, has consistently shown to predict ARDS [2–5] and Clara cell secretory protein 16 (CC16, formerly known as Clara cell secretory protein-16) produced in the conductive airways has been claimed to have this ability also [3].

It is not known whether these biomarkers of alveolar damage and conductive airway damage, respectively, can predict one-month clinical respiratory prognosis. Current measures of respiratory failure (e.g., PaO$_2$/FiO$_2$ ratio) do not seem to capture which intensive care patients are at risk of persistent ventilator-dependent respiratory failure for one month or more.

Berlin ARDS criteria are highly useful in many patients for guiding treatment [6]; however, many patients with severe acute respiratory failure get excluded from the ARDS diagnosis because of lack of relevant radiological findings fulfilling the criteria, and some patients without alarming baseline PaO$_2$/FiO$_2$ ratios may have a very poor respiratory prognosis. Clinical focus in intubated patients has been largely centered on acute syndromes within the first week after admission. However, less attention has been given to one-month respiratory prognosis, a clinically important endpoint.

SPD, a 43-kDa member of the collectin superfamily, is a part of lung surfactant and has been shown to have an important role in the innate immune system by working as a pattern recognition molecule [7]. Additionally, SPD promotes chemotaxis of antigen-presenting cells [8] and influences the function of lymphocytes and neutrophils [9, 10]. In a murine transgenic model, mice overexpressing SPD seemed to be protected against lung damage in oxidative stress [11]. Increases in vascular phase SPD have been associated with acute lung injury and mortality [2].

Club cells are situated primarily in the terminal bronchioles [12]. The dominant secreted substance from these cells is CC16, a 16-kDa polypeptide involved in immunoregulation [13, 14]. CC16 decreases in chronic lung damage, and among smokers, CC16 is reduced proportionally to the number of pack years [15]. CC16 increases in plasma when airways are stimulated with endotoxin [16]; however, this has been disputed [17]. These two biomarkers represent ways of identifying alveolar damage (SPD) and conductive airway damage (CC16).

The primary aim of this study was, among patients with acute ventilator-dependent respiratory failure and complete follow-up, to determine whether initial profound alveolar damage (high SPD) or damage to conductive airways (high CC16) is associated with ARDS and has a detectable clinical impact one month after intensive care admittance, i.e., failure to successfully wean the patient from mechanical ventilation.

**Methods**

**Study population**

This was a multicenter observational study based on the cohort of ICU patients recruited into the 1200-patient randomized controlled trial, the Procalcitonin And Survival Study (PASS) from 2006 to 2011 [18]. Data were collected according to the Good Clinical Practice guidelines [19], and follow-up was complete on the measures in the case report forms. Regarding use of mechanical ventilation, this was followed up for all patients, also when patients were discharged from the recruiting ICU and admitted to another ICU. All participants gave written informed consent, and ethical approval for the study was granted by the Regional Ethics Committee for Copenhagen and Frederiksberg Communes in Denmark (references: KF 01 272 753, KF 11 297 287).

To be eligible for the PASS trial, patients had to be at least 18 years of age, enrolled within 24 h of admission to the intensive care unit, and have an expected intensive care admission length of at least 24 h. Patients with known highly elevated bilirubin levels (≥40 mg/dL) or triglycerides (≥1000 mg/dL) were not eligible because of interference with procalcitonin measurements. Patients were recruited from nine ICUs across Denmark. In the PASS trial, patients were randomized to a proactive antibiotic strategy guided by biomarker levels (high-exposure group, n = 604) vs. a standard antibiotic strategy (standard exposure group, n = 596). Two recent publications
from the study describe the details [20, 21]. Mortality was unchanged by the antibiotic intervention [18]. The population for the current study was all primarily intubated patients from the PASS trial with sufficient serum for the bio-analysis at baseline (n = 758). The population was split into two subpopulations according to the geographical position of the site where the patient was recruited: a northern “learning cohort” (n = 405) and a southern “validating cohort” (n = 353). The study material includes a biobank with serum from all patients from all days in the ICU (n = 9915 samples). For simplicity, one month was defined as 28 days.

Biomarker measurement
Serum levels of SPD and CC16 were measured at baseline in uniplicate by commercially available ELISA assays (BioVendor Research Products ELISA kit, Brno, Czech Republic). The lower limits of detection were 0.01 ng/ml in the SPD kit and 0.046 ng/ml in the CC16 kit, respectively. No measurements were below the detection rate. Samples above the calibration interval were diluted.

Outcome assessment
Several endpoints were assessed in the analyses to explore the hypothesis:

1. “Not successfully weaning from mechanical ventilation within 28 days”: A patient who was weaned from respirator within 28 days and not re-intubated within the same period was considered to have been successfully weaned. Death within 28 days was considered a competing in these analyses.

2. “Alive and without ventilator ≥20 days within the first month”: Since death was frequent in this cohort (as in other ICU cohorts), we explored a combined “favorable” outcome of surviving and being independent of mechanical ventilation for ≥20 days.

3. ARDS according to the Berlin Criteria [6]: The endpoints were assessed using the case report form while in the initial ICU and post-ICU by finding all admissions to departments in Denmark; if the department was not able to administer mechanical ventilation, it was assumed that the patient was not using mechanical ventilation. If the department could administer mechanical ventilation, the patient chart was located and read to ascertain whether the patient received mechanical ventilation. Radiology was registered in the case report form. Bilateral opaque infiltrates not fully explained by other causes were considered suspicious for ARDS and were combined with the PaO2/FiO2 ratio in the definition. An ICU specialist judged whether the patient had ARDS (acute diagnosis in the case report form).

Statistical analyses
Comparisons of continuous data were made using Student’s t tests and Mann–Whitney U tests where appropriate. Chi-square tests for equal proportions were used to test categorical variables; at small numbers, Fisher’s exact test was used. Time-to-event analyses were performed using Cox proportional hazards models and Kaplan–Meier plots with corresponding log-rank tests. For analyses of persistent respiratory failure, a competing risk model was applied to account for the effect of deaths during follow-up. Multivariable analysis of the primary endpoint was performed adjusting for known and suspected predictors of persistent respiratory failure: surfactant protein D ≥85th percentile (≥525.6 ng/mL), club cell secretory protein 16 ≥85th percentile (≥42.75 ng/mL), lowest quartile PaO2/FiO2 ratio (vs. quartile 2-4), APACHE II score (continuous), age (continuous), severe sepsis/septic shock (present vs. not), chronic obstructive lung disease (COPD, yes vs. no), Charlson’s score ≥2 (vs. <2), gender (male vs. female) and estimated glomerular filtration rate (continuous). “Alive and without ventilator ≥20 days within the first month” and “ARDS” were analyzed using multivariable logistic regression analysis.

A power calculation was done for the smallest cohort. Conditions for the calculation were as follows: sample size 353, conventional border for type I error (0.05), exposure variable present in 15% (biomarker level above 85% percentile), endpoint (successful weaning within 28 days) present in 55% in the high-level biomarker group, variance inflation factor of 0.2 and detection limit of hazard ratio in a Cox proportional hazards model of 0.60. This resulted in a power of 0.80. Power calculation was done using the Study Size 3.0 package, Creostat, Frölunda, Sweden. Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC) and “R” version 3.0.2 (The R-project, http://www.r-project.org/).

The study was initiated and run by doctors at our research department (CHIP, Rigshospitalet) and the participating intensive care units (ICU). All data belong to the PASS study group.

Results
Between January 2006 and June 2011, nine intensive care units in Denmark recruited and followed 1200 critically ill patients. Serum was collected for all patients on all ICU days; however, in 75 patients, not enough serum was available to perform ELISA analysis. Additionally 367 patients were not intubated at baseline; 758 patients were included in the current study (Fig. 1). 405 in the “learning cohort” and 353 in the “validating cohort.” The baseline characteristics in the two cohorts are given in Table 1; the
most common primary reason for admission to the ICU was infection of different types, as given in Table 1.

Follow-up within 28 days after inclusion was complete both for the primary endpoint (weaning from ventilator-demanding respiratory) and for mortality in both cohorts.

The highest levels of SPD were found in patients with pneumonia and heart failure as primary cause of ICU admission (Fig. 2); no differences were noted for CC16 between any diagnostic categories (not shown).

**Successful weaning from mechanical ventilation within 28 days**

Failure to be successfully weaned from mechanical ventilation within 28 days was observed 105/405 (25.9%) in the “learning cohort” and 118/353 (33.4%) in the “validating cohort.” Death from all causes was considered a competing risk in all Cox regression analyses.

Patients with SPD above the 85th percentile (≥525.6 ng/mL) in the “learning cohort” were less likely to be successfully weaned from ventilator (adjusted HR 0.6 [95% CI 0.4–0.9], p = 0.0053); no association was found for CC16, and apart from SPD, only APACHE II score and severe sepsis/septic shock independently predicted reduced probability of successful weaning from mechanical ventilation within 28 days, Cox regression, as given in Table 2. After proposing and analyzing the 85th percentile cutoff in the “learning cohort”/northern cohort at 525.6 ng/mL SPD, all the above analyses were repeated in the “validating cohort”/southern cohort, using the cutoff established in the “learning cohort” (525.6 ng/mL).

The signal was unchanged; high SPD independently predicted a reduced chance for the patient successfully to be weaned from mechanical ventilation within 28 days (adjusted HR 0.6 [95% CI 0.4–1.0], p = 0.046, Table 2).

Since the population was heterogenous, the above analyses were repeated in both cohorts after excluding patients considered to have a some degree of non-reversible cause of persistent respiratory failure (heart failure, severe neurological disease and chronic interstitial lung disease); the signal was unchanged: northern (learning) cohort (n = 346): SPD ≥ 525.6 ng/mL: adjusted HR 0.6 [95% CI 0.4–1.0, p = 0.028] and southern (validating) cohort (n = 300): SPD ≥ 525.6 ng/mL: adjusted HR 0.6 [95% CI 0.4–1.0, p = 0.050].

The hazard function for successful weaning from mechanical ventilation according to SPD serum level (the 15% patients with highest SPD, ≥525.6 ng/mL) for the entire cohort (n = 758) seemed not only to be different in the early course of the ICU admission; curves separate increasingly throughout the 28-day observation period, and patients with high SPD also had a substantially increased incidence of death while intubated, as shown in Fig. 3.

**Alive and without ventilator ≥20 days within the first month**

In the learning cohort, 211 of 405 patients were “alive and without ventilator ≥20 days within the first month.”
In the validating cohort, this number was 154/353. In both cohorts, SPD ≥ 85th percentile (≥ 525.6 ng/mL) was an independent predictor of the patient being “alive and without ventilator ≥ 20 days within the first month” (Fig. 4).

“Acute respiratory distress syndrome” according to Berlin criteria
In total, 31 (4.1%) patients fulfilled the ARDS Berlin definition at admission to the ICU. All patients were assessed for ARDS at baseline, but were not followed for this after discharge from the ICU. High SPD also independently predicted ARDS at baseline; however, CC16 did not predict these endpoints (Table 3).

Patients with SPD ≥ 85th percentile (≥ 525.6 ng/mL) also had a high incidence of death from all causes as compared with patients with an SPD < 85th percentile, as shown in Additional file 1: eFig 1.

Discussion
The current study shows, in a well-defined cohort of 758 intubated critically ill patients, that profound alveolar damage at ICU admission, measured using SPD, increases the risk that the patient has ARDS, and substantially reduces the chance that patients can breathe on own conditions, without mechanical ventilation, one month after admission to the intensive care unit. Patients with high SPD also had a high risk of 28-day all-cause mortality. To acknowledge the competing risk of death, the main analysis was performed as a competing risk model. Additionally, an analysis of the endpoint “alive and without ventilator ≥ 20 days within the first month” was performed. The signal was unchanged; a high SPD was an independent predictor of this endpoint also. The effect was detected in a “learning cohort” and validated in a “validating cohort,” geographically separated. Results in both cohorts were robust to adjustment for nine other

Table 1 Baseline characteristics of the patients in the two cohorts

| Characteristics                              | Learning cohort (northern) | Validating cohort (southern) |
|----------------------------------------------|----------------------------|-------------------------------|
| Age (year) (median, IQR)                     | 68 (59–77)                 | 67 (57–75)                    |
| Apache II score (median, IQR)                | 21 (15–28)                 | 19 (14–25)                    |
| Body mass index (kg/m², median, IQR)         | 24.7 (22.8–27.7)           | 24.7 (22.2–27.7)              |
| eGFR (mL/min/1.73 m²)                        | 48.5 (26.4–78.9)           | 58.8 (33.5–93.5)              |
| PaO2/FiO2 (Kpa, median, IQR)                 | 19.4 (11.6–29.2)           | 21 (13.6–28.9)                |
| Surfactant protein D (ng/mL, median, IQR)    | 133.5 (77.3–308.0)         | 112 (63.5–240.7)              |
| Club cell secretory protein 16 (ng/mL, median, IQR) | 25.4 (10.6–37.4) | 20.2 (7.7–37.9)              |
| Severe sepsis/septic shock, n (%)            | 158 (39.0)                 | 149 (42.2)                    |
| Charlson’s comorbidity index, n (%)          |                            |                               |
| 0                                            | 130 (32.1)                 | 136 (38.5)                    |
| 1                                            | 139 (34.3)                 | 108 (30.6)                    |
| 2                                            | 79 (19.5)                  | 65 (18.4)                     |
| 3                                            | 34 (8.4)                   | 30 (8.5)                      |
| 4                                            | 13 (3.2)                   | 8 (2.3)                       |
| 5                                            | 6 (1.5)                    | 2 (0.6)                       |
| 6                                            | 4 (1.0)                    | 3 (0.9)                       |
| 7                                            | 0 (0.0)                    | 1 (0.3)                       |
| COPD, n (%)                                  |                            |                               |
| 81 (20.0)                                    |                            | 75 (21.3)                     |

y, years; IQR, interquartile range; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate—calculated by the Cockroft–Gault formula.
known or suspected predictors of respiratory failure [22, 23]. Additionally, the association is biologically plausible, since SPD is a documented part of the alveolar surfactant with immunological properties as a pattern recognition molecule, and serum SPD increases when alveolar damage emerges so a leakage to the blood can occur [7, 24, 25]. Almost half of the patients with high SPD were not capable of breathing on own conditions after one month.
was reached, compared to approximately one-fourth of those with SPD below the cutoff.

Opposite, CC16, a marker primarily produced in the conductive airways, did not predict the endpoint in any analysis.

The current results should be interpreted in context to the not easily recognized pathophysiological changes taking place in acute ventilator-dependent respiratory failure, sometimes leading to the clinical picture of acute respiratory distress syndrome (ARDS): diffuse damage to alveolar epithelial cells, including alveolar type II cells and vascular endothelium, breakdown of the basal membrane in the alveoli and consequent leakage of surfactant components to the blood. This is accompanied by hemorrhagic intra-alveolar deposition of platelets, protein and fibrin components eventually forming hyaline membranes [26].

Thus, our results indicate that patients who have an early increase in SPD more often progress into pathophysiological changes that are not easily reversible and changes that cause the phenotype of persistent ventilator-dependent respiratory failure. Our findings regarding PaO2/FiO2 ratio, an important acute parameter for the ICU physician, underline the need for pathophysiological markers like SPD to identify patients at early risk of persistent respiratory failure, since an unfavorable PaO2/FiO2 ratio in the lowest quartile was not a consistent predictor of poor respiratory prognosis after one month.

The knowledge provided by measuring SPD early does have important implications for predicting outcome, and it does increase the understanding of how and when the decisive pathophysiological steps leading to this feared clinical syndrome occur, but even more importantly, this knowledge could help at admission, identifying the most suitable candidates for trials applying experimental lung interventions in patients at high risk of developing persistent respiratory failure. Prone positioning has been demonstrated to be effective in patients with ARDS [27]; however, our results suggest that patients with a predicted high risk of persistent respiratory failure (i.e., highest SPD) should be enrolled in trials testing experimental lung interventions even before ARDS develops, in order to improve the prognosis [28]. ARDS awareness is of key importance in these vulnerable patients, so timely and effective interventions can be initiated. However, current reports show that ARDS is often not recognized, even when present [22]. Additionally, many patients who end up with persistent respiratory failure after one month may not have fulfilled ARDS criteria previous to this, and in some patients, an early warning by a biomarker, before ARDS develops, may provide a possibility for early intervention, even before clinical signs of poor prognosis can be realized. Thus, it seems reasonable to supplement increasing ARDS awareness with biomarkers of acute lung damage like SPD and probably others. In a rat model of ARDS, soluble receptor for advanced glycation end products (sRAGE) seemed to reflect alveolar type I cell injury, and this was also observed in humans [29, 30], and recently, it has been demonstrated that a strong negative correlation exists between alveolar fluid clearance rate and plasma sRAGE in a murine model as well as in humans [31]. Thus, sRAGE and SPD may provide complementary information on the pathophysiological changes taking place in the alveolar epithelium.

This knowledge does draw the attention to two issues of pivotal importance: i) that novel and experimental alveoli-protecting interventions should be instituted in a personalized manner—what works for one critically ill patient (with altered SPD, sRAGE and possibly other signals of profound lung damage) may not work for another patient with low SPD and no other significant signs of profound lung damage, and ii) that in patients with early signs of profound lung damage, experimental alveoli-protecting interventions should probably be tested in trials to reduce development of long-term respiratory failure.
Strengths and limitations

The current study is an observational study with the built-in limitations this implies. Not all patients in the cohort had lung biomarker measurements (75 patients in the cohort had insufficient volume of serum, and we cannot expand our conclusions to the patients where biomarker measurements were not taken). We cannot document that awareness of ARDS was sufficient; however, this is not unique to our cohort [22]. Many factors that occur after the initial event that led to ICU admission may have influenced the development of persistent respiratory failure, which are tidal volumes, PEEP adjustments and the timing of these, transfusions, critical illness neuropathy and others. We could not control for all these factors, and especially timing of PEEP adjustments are, to some extent, still disputed. However, factors not present at baseline and therefore not possibly captured by the biomarkers at baseline will tend to underestimate the predictive power of the biomarkers. Optimally, biomarkers of lung damage should have been measured daily. The strengths of the study are (1) the relatively high sample size, (2) the complete follow-up for the endpoints.
due to good clinical practice-based clinical monitoring and follow-up based on the Danish hospital registers and (3) the completeness of data on a wide variety of clinical, biochemical, radiological and microbiological data in these patients.

Optimally, the results should be validated in another cohort of intubated ICU patients with complete follow-up on mechanical ventilation and mortality for 28 days, and where these two biomarkers were analyzed. Since we could not identify such a population by searching PubMed and EMBASE, we decided to split the cohort up according to geographical criteria to mimic that the validating cohort was another cohort. This strategy can be criticized, and our results should be further validated.

In summary, a high SPD level at baseline is associated with a very high absolute risk of the patient not being successfully weaned from mechanical ventilation within a month, and a high risk of dying while intubated. When adjusted for other predictors of respiratory failure, high SPD level at baseline independently predicts persistent respiratory failure during mechanical ventilation in critically ill patients. Acknowledging that ICU populations are often heterogenous and that other reasons may have accounted for some of the cases of persistent respiratory failure, we repeated all the main analyses while excluding patients with heart failure, chronic interstitial lung disease and severe neurological diseases; all these analyses confirmed the findings regarding the lung damage biomarkers.

The results from the current study indicate that high impact insults on the lungs, early in the ICU course, contribute substantially to the development of later persistent respiratory. Importantly, early SPD blood measurements can reveal evidence of such profound lung damage. This knowledge could be used in updated diagnostic and prognostic models regarding respiratory failure and ARDS in critically ill patients. If our results regarding SPD and prognosis can be verified in other cohorts, SPD measurements could be added to the ARDS criteria, since SPD seems to predict both respiratory prognosis and overall prognosis and, importantly, is linked to pathophysiology taking place in the alveoli. Additionally, SPD measurements could be used to select patients for trials on novel experimental lung interventions initiated in high-risk patients at ICU admission before ARDS and eventually irreversible/persistent respiratory failure develops.

### Authors’ contributions

JUJ, TSI and JDL had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed substantially to conception and design, or acquisition of data, or analysis and interpretation of data. JUJ and JDL drafted the article. JUJ, TSI and JDL were involved in the statistical analysis. JUJ, JDL and BL obtained funding. All authors provided administrative, technical and material support. PLI and SRO were involved in the laboratory analysis. All other authors revised it critically for important intellectual content. All authors read and approved the final manuscript.

### Additional file

**Additional file 1.** Death from all causes according to level of surfactant protein D. Y-axis is cumulative risk of death. Bold line is for patients with low surfactant protein D; stipulated line is for patients with high surfactant protein D. Grey areas are 95% confidence intervals.

### Table 3. Acute respiratory distress syndromea according to Berlin criteria—multivariable logistic regression

| Biomarker and Definition                                      | Learning cohort (northern) | Valuating cohort (southern) |
|---------------------------------------------------------------|-----------------------------|-----------------------------|
|                                                               | $P$ value | Odds ratio | 95% CI for OR | P value | Odds ratio | 95% CI for OR |
| Surfactant protein D ($\geq \text{85th percentile in “learning cohort,”}$ $\geq 525.6 \text{ ng/mL vs.} < 525.6 \text{ ng/mL}$) | 0.042a | 3.4 | 1.0 | 11.4 | 0.003a | 8.4 | 2.0 | 35.4 |
| Club cell secretory protein 16 ($\geq \text{85th percentile in “learning cohort,”}$ $\geq 42.8 \text{ ng/mL vs.} < 42.8 \text{ ng/mL}$) | 0.14 | 2.6 | 0.7 | 9.7 | 1.0 | 0.96 | 0.20 | 4.5 |
| PaO2/FiO2 (Q1 vs. Q2-Q4)                                     | 0.076 | 2.9 | 0.9 | 9.1 | 0.001a | 9.3 | 2.6 | 33.7 |
| Apache II score (per score unit increase)                    | 0.23 | 1.025 | 0.984 | 1.067 | 0.57 | 1.023 | 0.946 | 1.106 |
| Age (per year increase)                                      | 0.56 | 1.015 | 0.965 | 1.067 | 0.26 | 0.974 | 0.93 | 1.02 |
| Severe sepsis/septic shock (vs. milder or no infection)      | 0.19 | 2.1 | 0.68 | 6.8 | 0.06 | 3.6 | 0.96 | 13.6 |
| Charlson’s comorbidity index $\geq 2$ vs. $< 2$               | 0.23 | 0.41 | 0.10 | 1.7 | 0.12 | 0.28 | 0.053 | 1.42 |
| Chronic obstructive pulmonary disease (yes vs. no)           | 0.74 | 0.76 | 0.15 | 3.8 | 0.65 | 1.43 | 0.30 | 6.7 |
| Gender (male vs. female)                                     | 0.32 | 0.56 | 0.18 | 1.74 | 0.67 | 1.30 | 0.40 | 4.2 |
| Estimated glomerular filtration rate (per ml increase)       | 0.19 | 1.005 | 0.998 | 1.011 | 0.61 | 1.003 | 0.992 | 1.01 |

Adjusted logistic regression risk estimates for known, suspected and explored predictors of ARDS. Abbreviations: Q1: quartile 1

Biomarker levels were not known for radiologists and ICU physicians who diagnosed ARDS

OR, odds ratio

*a* All severities (mild, moderate, severe) of ARDS were counted
Author details

1 CHIP/Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen Ø, Denmark. 2 Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark. 3 Department of Anesthesia and Intensive Care, Copenhagen University Hospital, Hillerød, Denmark. 4 Department of Anesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark. 5 Department of Anesthesia and Intensive Care, Copenhagen University Hospital, Gentofte, Denmark. 6 Department of Anesthesia and Intensive Care, Copenhagen University Hospital, Glostrup, Denmark. 7 Department of Anesthesia and Intensive Care, Aarhus University Hospital, Aarhus, Denmark. 8 Department of Anesthesia and Intensive Care, Copenhagen University Hospital, Hvidovre, Denmark. 9 Department of Anesthesia and Intensive Care, Copenhagen University Hospital, Herlev, Denmark. 10 Centre for Thrombosis and Hemostasis, Rigshospitalet, Copenhagen University Hospital, Copenhagen Ø, Denmark. 11 Centre for Respiratory Medicine and Allergy, University South Manchester Hospital NHS Foundation Trust and University of Manchester, Manchester, UK.

Acknowledgements

The authors wish to thank the Procalcitonin And Survival Study Data and Safety Monitoring Board for the primary study: H. Musar (Chair), J. Chastre, H. Schanenhedyer, C. Pedersen and the Procalcitonin And Survival Study Group (PASS-group): M. Steensen, K. Thorning, M. Bestle, D. Strange, A. Ø. Lauritsen, P. Sæ-Jensen, N. Reiter, N. E. E. Drenck, P. Fjeldborg, Z. Fox, J. Kiær, D. Kristensen, M. B. Rasmussen, C. S. V. Hallas, M. Zacho, C. Østergaard, P. L. Petersen, S. Hougaard, T. Mantoni, L. Nebrich, A. Bentdtsen, L. H. Andersen, F. Bærentzen, Andreas Eversbusch, B. Bømler, R. Martusevicius, T. Nielsen, P. M. Båstadstølletken, U. Grevedt, P. Hallas, A. Lindhardt; T. Galle, K. Graesser, E. Holm-Hansen, H. Christensen; P. Gregeresen, L. M. Pedersen, L. C. Hallengreen, J. Rye, J. Cordt, K. R. Madsen, P. R. C. Kirkegaard, L. Findsen, L. H. Nielsen, D. H. Pedersen, J. H. Andersen, C. Albrechtsen, A. Jacobsen, T. Jansen, A. G. Jensen, H. H. Jørgensen, M. Vazin, L. Lipsius, M. Skielboe, B. Thage, C. Thorst, M. Uldbjerg, E. Anderlo, M. Engsø, F. Hani, R. B. Jacobsen, L. Mulla, U. Skram, T. Waldau, T. Faber, B. Andersen, I. Giffelsberg, A. Christensen, C. Hartmann, R. Albrecht, D. S. Dinesen, K. Grani, M. Ibsen, J. A. Petersen, P. Carl, E. Gade, D. Soleved, C. Heiring, M. Jørgensen, K. Ekelund, A. Afshari; N. Hammer, M. Bitsch, J. S. Hansen; C. Wamberg; T. D. Clausen; R. Winkel; J. Huusom; D. L. Buck; U. Grevedt, K. Lenz; P. Mellado; H. Karacan, J. Hiedestål, H. Høggaard, J. Højbjerg, J. Højlund, S. Hestad, M. Østergaard, N. Wesche; S. A. Nielsen, H. Christensen, H. Blom; C. H. Jensen, K. Nielsen, N. G. Holler, C. D. Rossau, M. Glærebøe; M. B. Wraner; C. B. Thomesen, B. Rasmussen, C. Lund-Rasmussen, B. Bech, K. Bjergaard, L. Spliid, L. L. W. Nielsen, K. M. Larsen, M. Goldinger, D. Illum, C. Jessen, A. Christiansen, A. Berg, T. Elkmann, J. A. K. Pedersen, M. Simonsen, H. Jønsen; H. Alstrøm, C. Svane, A. Engquist.

Competing interests

All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf and declare: Dr. Vestbo reports personal fees from GlaxoSmithKline, personal fees from Chiesi Pharmaceuticals, personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, all outside the submitted work; Dr. Jensen reports other from Novartis, outside the submitted work. All authors declare: no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Funding

This work was supported by the Danish National Research Foundation [Grant No. DNRF126] (CHIP & PERSIMUNE), the Lundbeck Foundation and the Idella Foundation.

Ethical approval

The study was approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The trial has been approved by the regional ethics committee (KF 01 272 753, KF 11 297 287).

Ethics, consent and permissions

All participants gave written informed consent, including consent to publish the results, and ethical approval for the study was granted by the Regional Ethics Committee for Copenhagen and Frederiksberg communes in Denmark (references: KF 01 272 753, KF 11 297 287).

Summary for social media/Tweet

Biomarkers help physicians to identify patients who will not recover to breathing on own conditions: New targeted treatments are needed.

Received: 26 July 2016 Accepted: 2 November 2016

Published online: 21 November 2016

References

1. Sellares J, Ferrer M, Cano E, Loureiro H, Valencia M, Torres A. Predictors of prolonged weaning and survival during ventilator weaning in a respiratory ICU. Intensive Care Med. 2011;37:775–84.
2. Eiser MD, Parsons P, Matthy MA, Ware L, Greene K. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax. 2003;58:983–8.
3. Determann RM, Millo JL, Waddy S, Lutter R, Garrard CS, Schultz MJ. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study. BMC Pulm Med. 2009;49.
4. Calfee CS, Ware LB, Glikdén DV, Eiser MD, Parsons PE, Thompson BT, Matthay MA. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med. 2011;39:711–7.
5. Todd DA, Marsh MJ, George A, Henderson NG, Barr H, Sebastian S, Clark GT, Koster G, Clark HW, Postle AD. Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children. Pediatr Crit Care Med. 2010;11:82–91.
6. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, Brochard L, Brewer E, Esteban A, Gattinoni L, Rhodes A, Slutsky AS, Vincent JL, Rubenfeld GD, Thompson BT, Ranieri VM. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38:1573–82.
7. Crouch E, Wright JR. Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol. 2001;63:521–54.
8. Crouch EC, Persson A, Griffin GL, Chang D, Senior R. Interactions of pulmonary surfactant protein D (SP-D) with human blood leukocytes. Am J Respir Cell Mol Biol. 1995;12:410–5.
9. Borron PW, Crouch EC, Lewis JF, Wright JR, Possmayer F, Fraher LJ. Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. J Immunol. 1998;161:4599–603.
10. Madan T, Eggleton P, Kishore U, Strong P, Aggarwal SS, Sarma PU, Reid KB. Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect Immun. 1997;65:3171–9.
11. Jain D, Atochina-Vasserman EN, Tomer Y, Kadile H, Beers MF. Surfactant protein D protects against acute hyperoxic lung injury. Am J Respir Crit Care Med. 2008;178:805–13.
12. Czut E, Cohen PE. Ultrastructure and cytochemistry of Clara cells. Am J Pathol. 1971;62:127–41.
13. Bernard AD, Dumount X, Roels H, Lauwerys R, Dierryck I, De Ley M, Stroobant V, de Hoffmann E. The molecular mass and concentrations of protein 1 or Clara cell protein in biological fluids: a reappraisal. Clin Chim Acta. 1993;223:189–91.
14. Johansson S, Wennergren G, Aberg N, Rudin A. Clara cell 16-kd protein downregulates T(H)2 differentiation of human naive neonatal T cells. J Allergy Clin Immunol. 2007;120:308–14.
15. Bernard A, Roels H, Bücheler JP, Lauwerys R. Decrease of serum Clara cell protein in smokers. Lancet. 1992;339:1620.
16. Arsalane K, Breckkaert F, Knoops B, Wieder M, Toubage G, Bernard A. Clara cell specific protein (CC16) expression after acute lung inflammation induced by intratracheal lipopolysaccharide administration. Am J Respir Crit Care Med. 2000;161:162–4.
17. Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest. 2009;135:1440–70.
18. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Graup J, Lundgren JD. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39:2048–58.

19. Agency EM. Note for Guidance on Good Clinical Practice, EMEA (European Medicines Agency) [Consensus document]. July 2002. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. Accessed Jan 5, 2014.

20. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, Thomberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Graup J, Lundgren JD. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39(9):2048–58.

21. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, Thomberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Graup J, Lundgren JD. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open. 2012;2:e000635.

22. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson M, Tilley J, Thompson BT, Slutsky AS, Pesenti A, Investigators LS, Group ET. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800.

23. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson M, Tilley J, Thompson BT, Slutsky AS, Pesenti A, Investigators LS, Group ET. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800.

24. Gaunsoeb MQ, Rasmussen KJ, Beers MF, Atochina-Vasserman EN, Hansen S. Lung surfactant protein D (SP-D) response and regulation during acute and chronic lung injury. Lung. 2013;191:295–303.

25. Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Raber S, Rosset S, Mancebo J, Siriot M, Hilbert G, Bengler C, Richette G, Gourrier M, Bayle F, Boulind G, Lefay V, Girard R, Baboi L, Alyzec L. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159–68.

26. Zhu B, Li Z, Jiang L, Du B, Jiang Q, Wang M, Lou R, Xi X. Effect of a quality improvement program on weaning from mechanical ventilation: a cluster randomized trial. Intensive Care Med. 2015;41:1781–90.

27. Uchida T, Shirasawa M, Ware LB, Koijma K, Hata Y, Makita K, Mednick G, Matthay MA, Matthay MA. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173:1008–15.

28. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickham N, Matthay MA, Network NA. Plasma receptor for advanced glycation end-products and clinical outcomes in acute lung injury. Thorax. 2008;63:1083–9.

29. Jabaudon M, Blondonnet R, Roszyk L, Bouvier D, Audoard J, Clairefond G, Fournier M, Marceau G, Dechelotte P, Pereira B, Vaxelaire M, Constantin JM. Soluble receptor for advanced glycation end-products predicts impaired alveolar fluid clearance in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2015;192:191–9.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at springeropen.com